This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-25 and is reviewed periodically as new material appears.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Israel has used Palestinian children as human shields in Gaza in violation of Geneva conventions. Human rights groups have said that "even if Hamas were using human shields", Israel must still abide by international law, especially the principle of proportionality. In May 2023, before the beginning of the Gaza war, Defence for Children International – Palestine (DCIP) had already documented that five children had been used as human shields by the Israeli army since the beginning of that year, with two of the victims being 2-year-old twins. According to a 2024 Haaretz investigation based on many Israeli soldiers' testimony, Palestinian teenagers, adults, and occasionally elderly men are regularly used as human shields to explore the tunnel network in the Gaza Strip. These shawashim are dressed up, apart from sandshoes, to look like Israeli soldiers, handcuffed, blindfolded and, with a video camera attached to their bodies, sent into houses where Hamas combatants are suspected to hide, or into tunnels that might be booby-trapped. The practice is said to be widely known to IDF field commanders. Palestinians were used when neither sniffer dogs nor drones were available. An October 2024 investigation by CNN found that while the scale and scope of the practice was unknown, testimony from civilians and an Israeli soldier showed Israel's use of Palestinians as human shields was widespread across the Gaza Strip.
In American butchery, the sirloin steak is a cut of beef from the sirloin, the subprimal posterior to the short loin where the T-bone, porterhouse, and strip steaks are cut. The sirloin is divided into several parts. The top sirloin is the most prized part and is sold under that name. The bottom sirloin, which is less tender and much larger, is typically sold simply as "sirloin steak". The bottom sirloin connects to the sirloin tip roast. Sirloin steak is defined differently in different countries.
=== Early prototypes and barriers to entry: 1920s–1990s === In 1927, Joseph Robinson applied for a patent for an electronic vaporizer to be used with medicinal compounds. The patent was approved in 1930 but the device was never marketed. In 1930, the United States Patent and Trademark Office reported a patent stating, "for holding medicinal compounds which are electrically or otherwise heated to produce vapors for inhalation." In 1934 and 1936, further similar patents were applied for. The earliest e-cigarette can be traced to American Herbert A. Gilbert. In 1963, Gilbert applied for a patent for "a smokeless non-tobacco cigarette" that involved "replacing burning tobacco and paper with heated, moist, flavored air". This device produced flavored steam without nicotine. The patent was granted in 1965. Gilbert's invention was ahead of its time. However, it received little attention and was never commercialized because smoking was still fashionable at that time. Gilbert said in 2013 that today's electric cigarettes follow the basic design set forth in his original patent. The Favor cigarette, introduced in 1986 by public company Advanced Tobacco Products, was another early noncombustible product promoted as an alternative nicotine-based tobacco product. Favor was conceptualized by Phil Ray, one of the founders of Datapoint Corporation and inventors of the microprocessor. Development started in 1979 by Phil Ray and Norman Jacobson.
Sources: en.wikipedia.org
{\displaystyle {\begin{aligned}{\frac {dS}{dt}}&=\nu N(1-P)-\mu S-\beta {\frac {I}{N}}S\\[8pt]{\frac {dI}{dt}}&=\beta {\frac {I}{N}}S-(\mu +\gamma )I\\[8pt]{\frac {dV}{dt}}&=\nu NP-\mu V\end{aligned}}}
=== Education === Humphreys graduated from Chickasha High School (Chickasha, Oklahoma) in 1948. He then attended Colorado College, graduating with his BA in 1952. He attended Seabury-Western Theological Seminary (in Evanston, Illinois), graduating with the MDiv degree in 1955. In 1965, he entered graduate school at Washington University to pursue a PhD in sociology. His dissertation adviser was Lee Rainwater. Humphreys obtained two pre-doctoral research fellowships from the National Institute of Mental Health to fund his dissertation research. He completed his dissertation in 1968, graduating with his PhD in that year. He published the dissertation as Tearoom Trade: Impersonal Sex in Public Places in 1970. His book won the C. Wright Mills Award from the Society for the Study of Social Problems in 1969. Due to the controversy around his research methods and the topic of his research, there was a failed attempt by the chancellor of Washington University to rescind his PhD.
==== Cell culture using droplet-based microfluidics ==== Droplet-based microfluidic systems provide an analytic platform that enables the isolation of single cells or groups of cells in droplets. This tool offers high-throughput for cell experiments since droplet-based microfluidic systems can generate thousands of samples (droplets) per second. Compared with cell culture in conventional microtiter plates, microdroplets from μL to pL volumes reduce the use of reagents and cells. Additionally, automated handling and continuous processing allow assays to be carried out more efficiently. The isolated environment in an encapsulated droplet helps analyze each individual cell population. High-throughput cell culture experiments, for example, testing the behavior of bacteria, finding rare cell types, directed evolution, and cell screening are suitable for using the droplet-based microfluidic techniques.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.